Goodwin advised Rapport Therapeutics on the fundraising. Rapport Therapeutics announced the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the...
You must be a Standard 1 Year member to access this content.
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Rapport Therapeutics, Inc. on the deal. Rapport Therapeutics, Inc. announced its launch with a $100 million Series A financing from Third Rock Ventures, ARCH...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Alnylam Pharmaceuticals, Inc. on the deal, while Davis Polk advised the representative of the initial purchasers. Alnylam Pharmaceuticals, Inc. announced its inaugural offering...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced its private placement transaction with a select group of institutional investors to issue...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Asher Biotherapeutics on the deal. Asher Biotherapeutics announced the closing of its Series B financing, which raised $108 million. The financing was led by...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Repertoire Immune Medicines on the deal. Repertoire Immune Medicines announced the completion of its $189 million Series B financing. Joining Flagship Pioneering, Repertoire’s...
You must be a Standard 1 Year member to access this content.
